Detalhe da pesquisa
1.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25088940